CELONIQUE and ULTIMA launched the DEEP CELL REBUILD TECHNOLOGY study in December 2025. At the time of this report, the study is ongoing in Shanghai.
The study involves 40 participants at the MAIO Beauty Clinic, with professional support from the ROYAL Life Group.
Daniel Matthieu, CEO of CELONIQUE, coordinates and supervises the project, overseeing consistent professional standards and study protocols aligned with an international approach.

The interim observations collected to date report visible and measurable changes. A lifting effect associated with targeted ULTIMA muscle stimulation was assessed after the initial treatments using professional skin analysis devices.
The report describes favourable changes in inflammatory markers in deeper skin layers following the combination of IONLIFT and CELONIQUE ION LIFT MULTI-PEPTIDE Gel. The development aims to support non-invasive application of a formulation containing collagen, Q10, peptides, vitamins and exosomes. The original report also proposes delivery to the basal cell layer; detailed methodology and final data are needed to establish this and evaluate the observations.
According to the interim report, most participants showed less visible pores, reduced wrinkle depth and a smoother, more even-looking complexion. Further favourable changes were observed as treatments continued.
Participant feedback has been very positive: treatments were described as painless, comfortable and well tolerated, and several participants chose to continue with further sessions. These favourable experiences do not establish that treatment is risk-free for everyone.
The study is ongoing, and further data are planned for release as the research progresses.
Editorial note: this historical report includes professional clarifications. Research observations, author opinions and participant experiences do not establish a guaranteed treatment outcome for everyone.




